Brazil Pharmaceuticals & Healthcare Report

Published 26 August 2015

  • 122 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Brazil Pharmaceuticals & Healthcare Report

BMI View: Continued focus on foreign investment along with the expansion of telemedicine and governmental action to improve medical access will keep Brazil and appealing destination for drugmakers and healthcare companies in coming years, particularly as the healthcare market remains an outperformer in the country . This appeal, however, will remain limited in the short to medium term as Brazil's troubled economy begins to negatively impact other industries including the healthcare and pharmaceutical industry which are beginning to experience budget cuts and revenue decreases.

Headline Expenditure Projections

Pharmaceuticals: BRL62bn (USD26bn) in 2014 to BRL66bn (USD21bn) in 2015; +6.4% in local currency terms and -19.5% in US dollar terms. Forecast in has been maintained from Q 3 15 .

Healthcare: BRL501bn (USD213bn) in 2014 to BRL538bn (USD173bn) in 2015; +7.4% in local currency terms and -18.7% in US dollar terms . Forecast in local currency has been revised downward from Q115 due to historic data.

Risk/Reward Index

Brazil scores 57.5 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fourth-most attractive pharmaceutical market in the Americas this quarter. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected in this quarter's RRI scores, primarily a result of the country's consistent economic growth and the government's commitment to promoting local industry.

Key Trends And Developments

  • In August, the Brazilian Senate proposed reforms to the legal framework of the country's health sector, including evaluating the possibility of prohibiting injunctions that favour costly or experimental procedures not approved by the Sistema Unico de Saude.

  • In August, Brazilian President Dilma Rousseff has renewed her commitment to providing adequate healthcare services across the country during the second anniversary of the 'More Doctors'...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2011-2019)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Brazil 2013-2019)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Brazil 2013-2019)
33
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Table: Economic Activity (Brazil 2010-2019)
41
Industry Risk Reward Ratings
42
Americas Risk/Reward Index
42
Brazil Risk/Reward Index
48
Rewards
48
Risks
48
Market Overview
50
Industry Trends And Developments
51
Epidemiology
51
Healthcare Sector
53
Brazil Pharmaceuticals & Healthcare Report Q3 2015
Brazil Pharmaceuticals & Healthcare Report Q3 2015
- Business Monitor International Ltd Page 4
- Business Monitor International Ltd Page 4
Table: Healthcare Resources (Brazil 2009-2014)
54
Table: Healthcare Personnel (Brazil 2009-2014)
54
Table: Healthcare Activity (Brazil 2009-2014)
55
Research & Development
55
Biotechnology
57
Clinical Trials
59
Regulatory Development
61
Competitive Landscape
68
Table: Top 10 Pharmaceutical Companies In Brazil By Sales In 2013
68
Click here to enter text
68
Generic Drugmakers
71
Pharmaceutical Distribution Sector
74
Pharmaceutical Retail Sector
76
Company Profile
78
Ach-/Biosint-tica
78
EMS Sigma
82
Eurofarma
85
Medley
88
Crist-lia
91
Sanofi
94
Pfizer
97
Merck & Co
100
Novartis
103
GlaxoSmithKline
106
Table: GlaxoSMITHKLINE'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil
109
Roche
110
Demographic Forecast
113
Table: Population Headline Indicators (Brazil 1990-2025)
114
Table: Key Population Ratios (Brazil 1990-2025)
114
Table: Urban/Rural Population & Life Expectancy (Brazil 1990-2025)
115
Table: Population By Age Group (Brazil 1990-2025)
115
Table: Population By Age Group % (Brazil 1990-2025)
116
Glossary
118
Methodology
120
Pharmaceutical Expenditure Forecast Model
120
Healthcare Expenditure Forecast Model
120
Notes On Methodology
121
Risk/Reward Index Methodology
122
Index Overview
123
Table: Pharmaceutical Risk/Reward Index Indicators
123
Indicator Weightings
124

The Brazil Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazil pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Brazil, to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Brazilian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%